Cite
APA Citation
de Alarcon, P. A., Matthay, K. K., London, W. B., Naranjo, A., Tenney, S. C., Panzer, J. A., Hogarty, M. D., Park, J. R., Maris, J. M., & Cohn, S. L. (2018). intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet, 2, 25–34. http://access.bl.uk/ark:/81055/vdc_100055342150.0x00000d